Novartis to spend $300 million to expand its development and manufacturing operations to bolster its push into biologic medicines. The company will spend $110 million to increase clinical manufacturing operations at its facility in Mengeš, Slovenia, and another $60 million to expand capacity at its site in Schaftenau, Austria.

In addition, the company plans to establish a biologics hub at its Basel, Switzerland, campus to complement an existing Novartis Institutes for BioMedical Research center.

The investments are part of Novartis’ efforts to weave its early-stage biotherapeutics portfolio into existing locations.